دورية أكاديمية
أعرض في EDS

An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.

التفاصيل البيبلوغرافية
العنوان: An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
المؤلفون: Fung AE; Pacific Eye Associates, California Pacific Medical Center, San Francisco, California, USA., Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW Jr, Esquiabro M
المصدر: American journal of ophthalmology [Am J Ophthalmol] 2007 Apr; Vol. 143 (4), pp. 566-83.
نوع المنشور: Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Elsevier Science Country of Publication: United States NLM ID: 0370500 Publication Model: Print Cited Medium: Print ISSN: 0002-9394 (Print) Linking ISSN: 00029394 NLM ISO Abbreviation: Am J Ophthalmol Subsets: MEDLINE
أسماء مطبوعة: Publication: 1999- : New York, NY : Elsevier Science
Original Publication: [Chicago, etc., Ophthalmic Pub. Co., etc.]
مواضيع طبية MeSH: Tomography, Optical Coherence*, Angiogenesis Inhibitors/*administration & dosage , Antibodies, Monoclonal/*administration & dosage , Choroidal Neovascularization/*drug therapy , Macular Degeneration/*drug therapy, Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized ; Choroidal Neovascularization/diagnosis ; Female ; Fluorescein Angiography ; Humans ; Injections ; Macular Degeneration/diagnosis ; Male ; Prospective Studies ; Ranibizumab ; Retreatment ; Treatment Outcome ; Visual Acuity ; Vitreous Body
مستخلص: Purpose: To evaluate an optical coherence tomography (OCT)-guided, variable-dosing regimen with intravitreal ranibizumab for the treatment of patients with neovascular age-related macular degeneration (AMD).
Design: Open-label, prospective, single-center, nonrandomized, investigator-sponsored clinical study.
Methods: In this two-year study, neovascular AMD patients with subfoveal choroidal neovascularization (CNV) (n = 40) and a central retinal thickness of at least 300 microm as measured by OCT were enrolled to receive three consecutive monthly intravitreal injections of ranibizumab (0.5 mg). Thereafter, retreatment with ranibizumab was performed if one of the following changes was observed between visits: a loss of five letters in conjunction with fluid in the macula as detected by OCT, an increase in OCT central retinal thickness of at least 100 microm, new-onset classic CNV, new macular hemorrhage, or persistent macular fluid detected by OCT at least one month after the previous injection of ranibizumab.
Results: At month 12, the mean visual acuity improved by 9.3 letters (P < .001) and the mean OCT central retinal thickness decreased by 178 microm (P < .001). Visual acuity improved 15 or more letters in 35% of patients. These visual acuity and OCT outcomes were achieved with an average of 5.6 injections over 12 months. After a fluid-free macula was achieved, the mean injection-free interval was 4.5 months before another reinjection was necessary.
Conclusion: This OCT-guided, variable-dosing regimen with ranibizumab resulted in visual acuity outcomes similar to the Phase III clinical studies, but required fewer intravitreal injections. OCT appears useful for determining when retreatment with ranibizumab is necessary.
التعليقات: Comment in: Am J Ophthalmol. 2007 Apr;143(4):679-80. (PMID: 17386275)
معلومات مُعتمدة: P30 EY014801 United States EY NEI NIH HHS
المشرفين على المادة: 0 (Angiogenesis Inhibitors)
0 (Antibodies, Monoclonal)
0 (Antibodies, Monoclonal, Humanized)
ZL1R02VT79 (Ranibizumab)
تواريخ الأحداث: Date Created: 20070328 Date Completed: 20070419 Latest Revision: 20220330
رمز التحديث: 20240628
DOI: 10.1016/j.ajo.2007.01.028
PMID: 17386270
قاعدة البيانات: MEDLINE
الوصف
تدمد:0002-9394
DOI:10.1016/j.ajo.2007.01.028